AbbVie Announces Collaboration with Calico to Develop New R&D Facility

Article

AbbVie and Calico announce a novel collaboration to accelerate the discovery, development, and commercialization of new therapies.

AbbVie and Calico, the Google-backed life sciences company, announced on Sept. 3, 2014 a novel R&D collaboration intended to help the two companies discover, develop, and bring to market new therapies for patients with age-related diseases, including for neurodegeneration and cancer.

Under the agreement, the companies will combine their complementary strengths to accelerate the availability of new therapies for age-related diseases. Calico will use its scientific expertise to establish a world-class R&D facility, with a focus on drug discovery and early drug development based in the San Francisco Bay Area. AbbVie will provide scientific and clinical development support and its commercial expertise to bring new discoveries to market.

Source: AbbVie

Recent Videos
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content